Document:

<PAGE>
                                                                   EXHIBIT 10.48

                             DISTRIBUTION AGREEMENT

***Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended, and the Commission's rules and
regulations promulgated under the Freedom of Information Act, pursuant to a
request of confidential treatment.

                  This agreement ("Agreement") is made and entered into as of
October 15, 1998, by and between Carme Cosmeceutical Sciences, Inc., a
Corporation ("Carme"), and ICN Pharmaceuticals, Inc., a Delaware Corporation
("ICN").

                  Senetek PLC ("Senetek") holds certain patents for Kinetin and
has granted its subsidiary Carme certain rights arising under the patents,
including the right to manufacture, have manufactured and sell products
containing Kinetin. ICN desires to market and sell in the ethical market channel
specific formulations containing Kinetin for use as a skin care product. Carme
is willing to grant ICN the right to market and sell such formulations subject
to the terms and conditions of this Agreement.

                  Accordingly, in consideration of the mutual promises,
covenants, and conditions set forth below, the parties agree as follows:

1.       DEFINITIONS

                  When used in this Agreement, each of the following capitalized
terms shall have the respective meaning set forth in this Article.

     1.1 "Affiliate" means, with respect to any Person, another Person
controlled by, controlling or under common set forth in this Article.

     1.2 "Authorized Channel" means the sale of the products in the ethical
market channel, including (by way of example and not limitation) physicians,
pharmacies, medical clinics, and HMO's, and other recognized prescription drug
channels.

         "*Filed Separately with the Commission*"

     1.4 "Best Efforts" shall mean that commercially reasonable degree of
effort, expertise, knowledge and resources which one skilled, able, familiar
with and experienced in the matters set forth herein would utilize and otherwise
apply with respect to fulfilling an obligation.

<PAGE>

     1.5 "Carme Confidential Information" means the Know-How, non-public
information concerning the Patents, Improvements, marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Carme to ICN.

     1.6 "Calendar Quarter" means a period beginning on the first day of
January, April, July or October and ending on the last day of March, June,
September, or December, respectively.

     1.7 "Contract Year" means the period beginning on the date of the initial
launch or any anniversary thereof during the Term and ending on the first to
occur of one (1) year after such date and the termination of this Agreement.

     1.8 "Disruption Period" means any period during which Carme is unable to
deliver Products to ICN which conform to the specifications and are manufactured
in compliance with section 5.2.3.

     1.9 "Improvement" means any information, discovery, creation, derivative
work, invention, or trade secret, whether or not patented or patentable or
copyrighted or copyrightable, that relates to or is based upon the Patents or
Know-How and is developed or otherwise acquired by either party or its
respective affiliates.

     1.10 "Know-How" shall mean such know-how, special knowledge, technical or
other information, whether or not patented or patentable, owned or controlled by
Carme or its Affiliates at any time prior to or during the term of this
Agreement specifically related to the development, manufacture or use of any
device relating to the Product.

     1.11 "ICN Confidential Information" means marketing, sales, financial,
scientific and other non-public and/or proprietary information concerning the
products, projects, business and

                                       2

<PAGE>

operations of ICN including the manufacture, use, or sale of the Products
disclosed by ICN to Carme.

     1.12 "Net Sales" as used herein, shall mean the gross amount billed for
commercial sales of the Products sold, or otherwise distributed to any party by
ICN, its Affiliates or its sublicenses (not including sales by ICN to its
Affiliates or sublicensees), less the following deductions:

                  "*Filed Separately with the Commission*"

     1.13 "Patents" means the patents and patent applications for Kinetin set
forth on Exhibit A.

     1.14 "Person" means an individual, legal entity, government or agency
thereof.

     1.15 "Product(s)" means the lotion formulation containing Kinetin as set
forth in Exhibit B (the "Lotion"), the cream formulation containing Kinetin as
set forth in Exhibit C (the "Cream"), and all line extensions and enhanced
formulations of the foregoing.

     1.16 "Specifications" means the specifications for the Lotion set forth in
Exhibit B and for the Cream set forth in Exhibit C.

     1.17 "Territory" means worldwide; "Core Territory" means the continental
United States, Alaska, Hawaii, Puerto Rico and Canada.

     1.18 "Term" means the period starting on the date of this Agreement and
ending upon the expiration of the last to expire of the Patents.

2.       GRANT OF RIGHTS TO SELL

     2.1 Grant. Carme hereby grants to ICN during the Term hereof the right to
sell the Products in the Authorized Channel within the Territory, subject to
terms of this Agreement (the "Rights").

                                       3

<PAGE>

     2.2 Non-Core Territories. In the event ICN does not launch the Product in
any market outside the Core Territory within two (2) years from the date of this
Agreement, ICN's rights in that market shall, at Carme's option on written
notice to ICN, become non-exclusive or terminate.

     2.3 Right of First Offer. During the Term hereof, ICN shall have the right
of first offer to obtain the right to sell in the Authorized Channel in the
Territory new and enhanced products, developed or otherwise acquired by Carme
and/or its affiliates, which utilized Kinetin analogues, including Zeatin, as
the primary active ingredient for use as a skin care product; provided, however,
that such right of first offer shall not apply with regard to products that are
protected through patents or other exclusivity as to, owned by, or vested in a
third party and as to which Carme or its Affiliates have not acquired the right
to grant marketing rights to others. ICN shall have sixty (60) days from the
date that Carme notifies ICN that such a new or enhanced product is to or may
become available for sale to deliver an offer to Carme setting forth in
reasonable detail the terms upon which ICN would purchase, market and resell
such product. If Carme elects not to accept ICN's offer (or if no offer is made
within such period), Carme shall be free to grant such rights to others on terms
no better to such other party than those last offered by ICN, (or, if Carme has
made a counter offer, on terms no better to such other party than those offered
by Carme to ICN exercise such rights itself, or any combination thereof, all in
Carme's sole and absolute discretion.

     2.4 Exclusivity. Carme shall not grant any other party the right to sell
the Products in the Authorized Channel in the Territory during the Term and
shall not grant the right to sell the Products with a concentration of Kinetin
of 0.1% or greater in any marketing channel within the Territory (the
"Exclusivity Right"). The Exclusivity Right may be terminated by Carme upon

                                       4

<PAGE>

notice given to ICN if ICN fails to meet any Minimum Purchase Requirement or
satisfy the Promotion Commitment, or as provided in section 2.2 above.

     2.5 No Other Rights. It is expressly understood that this Agreement grants
no rights to ICN for the sale of the Product or under the Patents except those
express rights set forth in Sections 2.1 through 2.4. Without limiting the
foregoing, it is understood and agreed that ICN has not right pursuant to this
Agreement to, and shall not, (i) sell or permit its customers to sell the
Products outside the Authorized Channel or the Territory, (ii) manufacture or
have made other than by Carme any Products (other than pursuant to Section 4.6
of this Agreement) or (iii) have any right with respect to Improvements except
as set forth in Section 2.3. Upon any termination of this Agreement, ICN shall
have no right of any kind with respect to the Products, Patents or Improvements
other than the right to complete the sale of Products then lawfully in its
possession subject to the payment of royalties pursuant to Section 3.3.2.
Nothing in the foregoing sentence shall diminish ICN's rights in any trademark
or other intellectual property owned by ICN and used in connection with the
Products.

3.       PURCHASE COMMITMENTS

     3.1 Initial Order. Concurrently with execution of this Agreement, ICN shall
issue a non-cancelable purchase order for "*Filed Separately with the
Commission*"units of the Lotion and "*Filed Separately with the
Commission*"units of the Cream (the "Initial Order").

     3.2 Minimum Purchase Requirements. During the first Contract Year, ICN
shall purchase not less than "*Filed Separately with the Commission*"unit (the
"Minimum Purchase Requirement"). The Minimum Purchase Requirement may be met
with units any combination of Products (including line extensions and/or
additional formulations) purchased by ICN pursuant to this Agreement. In advance
of each subsequent Contract Year, ICN and Carme shall agree on a reasonable
Minimum Purchase Requirement for that year. In the event the parties fail to
agree

                                       5

<PAGE>

on a reasonable minimum purchase requirement, Carme may at its option terminate
the Exclusivity Right. In the event ICN fails to meet the Minimum Purchase
Requirement, Carme's sole remedy shall be termination of this Agreement pursuant
to Section 9.2 below or termination of the Exclusivity Right pursuant to section
2.4 above.

     3.3 Payment.

         3.3.1 Base Price. Carme may send an invoice for the Base Price for
Product ordered by ICN at any time after shipment. ICN shall pay Carme such
amount within thirty (30) days of the date of such invoice. Late payments shall
be subject to a monthly processing fee of "*Filed Separately with the
Commission*"of the amount due or, if such amount is not permitted by law, the
maximum amount permitted by law. Shipping charges for the Initial Order shall be
invoiced upon shipment and paid by ICN as otherwise set forth in this Section
3.3.1.

         3.3.2 Royalties. In further consideration of the grant of the rights
under this Agreement, ICN shall pay to Carme a royalty of "*Filed Separately
with the Commission*"of Net Sales from the Products in the Core Territory
beginning in the second Contract Year; "*Filed Separately with the Commission*".
Royalties for other markets will be agreed separately based on prevailing market
conditions, (however the average royalty overall shall not exceed "*Filed
Separately with the Commission*"). The Royalty shall be paid by ICN to Carme
quarterly with respect to sales of the Products during each Calendar Quarter
within thirty (30) days after the end of such Calendar Quarter. Each royalty
payment shall be accompanied by a statement setting forth in reasonable detail
the basis for the calculation of the royalty amount paid. ICN shall permit Carme
reasonable access to the date necessary to audit such calculation upon request
from Carme provided that any such audit shall be conducted by independent
auditors. Any such audit shall be commenced by Carme no later than three (3)
years following the end of the relevant

                                       6

<PAGE>

contractual year, and no more than one such audit shall be conducted during any
twelve (12) month period.

         3.3.3 Adjustments to Base Price. At the end of the first Contract Year
and at the end of each following Contract Year, the Base Price, as previously
adjusted, shall be adjusted based on changes in actual costs during the just
completed Contract Year.

4. MANUFACTURE DELIVERY OF PRODUCTS

     4.1 Source. Products shall be manufactured by "*Filed Separately with the
Commission*" or such other manufacturer(s) as Carme may from time to time
designate. ICN shall have the right to conduct reasonable audits of any
manufacturing site designated by Carme. Any manufacturing site transfer shall be
performed in accordance with standards of good manufacturing practices for
cosmetic products.

     4.2 Orders. Orders for Products shall be delivered to Carme at the
following address:

                           Carme Cosmeceutical Sciences, Inc.
                           620 Airpark Road
                           Napa, CA 94558
                           Attention:  Purchasing Department

or at such other address as Carme may give ICN notice.

     4.3 Packaging and Labeling. The Products shall be packaged and labeled as
set forth in Exhibit D. ICN grants to Carme a license to utilize the trademarks,
service marks and other intellectual property necessary to package and label the
Products as specified in Exhibit C (the "Packaging License"). The Packaging
License shall expire upon the termination of this Agreement.

     4.4 Requirements Forecasts. ICN shall provide Carme with a rolling twelve
(12) month forecast of its requirements for Products under this Agreement to be
updated quarterly, and delivered to Carme at least thirty (30) days in advance
of the period forecasted. The first

                                       7

<PAGE>

 ninety (90) days of each forecast shall constitute a firm order that is not
subject to cancellation by ICN.

     4.5 Delivery. Carme shall use its best efforts to fulfill orders within
ninety (90) days of the date they are confirmed by Carme. Inability to fulfill
any order within ninety (90) days shall be deemed a Disruption Period. ICN may
not cancel any order after it is confirmed, provided the order is fulfilled
within ninety (90) days. Carme shall ship the Products from the place of
manufacture to such location within the Territory as ICN specifies in the Order.
ICN shall reimburse Carme for all reasonable costs of shipping, including
without limitation reasonable costs of insurance. Such costs shall be reflected
in invoices delivered pursuant to Section 3.3.1.

     4.6 Interim Manufacturing License. During any Disruption Period, ICN or its
designee shall have a non-exclusive license to use the Patents, Know-How and
Carme Confidential Information to produce the Products (the "License"). All
manufacturing of the Products pursuant to the License shall be completed in
compliance with the specifications set forth in this Agreement for the Products.
Carme shall make available to ICN (at ICN's expense, limited to the actual cost
of materials) during any Disruption Period any packaging and/or labeling
materials in the possession of Carme or Carme's contract manufacturers for the
Products. ICN shall have the right at any time during this Agreement to perform
technology transfer, manufacturing scale up, and manufacturing development for
the products at a site of ICN's choice. The License shall terminate upon the
first to occur of (a) notice from Carme to ICN that it has resumed production
and can deliver Products immediately or (b) termination of this Agreement.

5.      REPRESENTATIONS, WARRANTIES AND CERTAIN COVENANTS OF THE PARTIES

                                       8

<PAGE>

     5.1 Representations, Warranties and Covenants of ICN. ICN represents,
warrants and covenants as follows:

         5.1.1 Qualifications and Authorization. ICN is a corporation duly
formed, validly existing and in good standing in the state of Delaware with full
corporate power and authority to conduct its business as it is now conducted and
to enter into and perform this Agreement. ICN is duly licensed or qualified to
do business and is in good standing in each jurisdiction in which its operations
or ownership of assets in connection with this Agreement requires such licensing
or qualification.

         5.1.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by ICN with any of the provisions
hereof, will (i) violate or conflict with any provision of the Certificate of
Incorporation or Bylaws of ICN, (ii) violate, conflict with, or result in a
breach of any provision of, or constitute a default (or an event which, with
notice or lapse of time or both, would constitute a default) under, or result in
the creation of any encumbrance upon any of ICN's assets under, any of the
terms, conditions or provisions of any material contract, indebtedness, note,
bond, indenture, security or pledge agreement, commitment, license, lease,
franchise, permit, agreement, or other instrument or obligation to which ICN is
a party, or (iii) violate any statute, rule, regulation, ordinance, code, order,
judgment, ruling, writ, injunction, decree or award applicable to ICN, except,
in the case of each of clauses (i), (ii) and (iii) above, for such violations,
conflicts, breaches, defaults or creations of encumbrances which, in the
aggregate, would not have a material adverse affect on the business of ICN or
its ability to perform this Agreement.

                                       9

<PAGE>

         5.1.3 Compliance With Laws. ICN shall comply in all material respects
with any law, regulation, ordinance, order, injunction, decree or requirement
applicable to the marketing or sale of the Products.

         5.1.4 Marketing Efforts. ICN will promote and market the Products in a
manner consistent with its efforts for other products and general industry
practice. In connection with these efforts, ICN will spend during the first
Contract Year not less than "*Filed Separately with the Commission*"on
advertising and promotion related exclusively to the Products, with any
additional expenditures to be based on a review of sales trends for the Products
six months following launch (the "Promotion Commitment").

         5.1.5 Product Launch. ICN will begin marketing the product not later
than the end of the first Calendar Quarter of 1999, or shall, on the last day of
such Calendar Quarter, place a non cancelable order for not less than "*Filed
Separately with the Commission*" units of Products, with payment to be made in
accordance with section 3.2.2

         5.1.6 Packaging License. To the knowledge of ICN, the Packaging License
includes all the intellectual property rights necessary for Carme to produce the
packaging and labeling required by this Agreement.

     5.2 Representations and Warranties and Covenants of Carme. Carme
represents, warrants and covenants as follows:

         5.2.1 Qualifications and Authorization.Carme is a corporation duly
formed, validly existing and in good standing in the state of Delaware with full
corporate power and authority to conduct its business as it is now conducted and
to enter into and perform this Agreement. Carme is duly licensed or quliaified
to do business and is in good standing in each

                                       10

<PAGE>

jurisdiction in which its operations or ownership of assets in connection with
this Agreement requires such licensing or qualification.

         5.2.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by Carme with any of the
provisions hereof, will (i) violate or conflict with any provision of the
Certificate of Incorporation and Bylaws of Carme, (ii) violate, conflict with,
or result in a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a default), under,
or result in creation of any encumbrance upon any of Carme's assets under, any
of the terms, conditions or provisions of any material contract, indebtedness,
note, bond, indenture, security or pledge agreement, commitment, license, lease,
franchise, permit, agreement, or other instrument or obligation to which Carme
is a party, or (iii) violate any statute, rule, regulation, ordinance, code,
order, judgment ruling, writ, injunction, decree or aware applicable to Carme,
except, in the case of each of clauses (i), (ii) and (iii) above, for such
violations, conflicts, breaches, defaults or creations of encumbrances which, in
the aggregate, would not have materials adverse effect on the business of Carme
or its ability to perform this agreement.

         5.2.3 Products Standards. Carme warrants that the Products will be
manufactured in accordance with the Specifications and in compliance with the
existing master batch record and current good manufacturing practices for
cosmetic products, and that the Products will conform in all respects to the
Specifications when delivered to the shipper for shipment to the ICN. Any
changes in the master batch record, shall be pre-approved in writing by ICN and
Carme.

                                       11

<PAGE>

         5.2.4 Compliance with Law. Carme shall comply in all material respects
with any law, regulation, ordinance, order, injunction, decree or requirement
applicable to the manufacture, packaging, storage, shipment and sale of the
Products.

         5.2.5 Patents. Senetek owns the Patents. To the knowledge of Carme and
Senetek: (i) the Patents do not infringe upon the rights of any third party; and
(ii) the Patents are valid. In the event Senetek and/or Carme intends to file
any additional patent applications with respect to the Products, Carme shall, to
the extent possible to do so without impairing its intellectual property rights
or violating agreements with or intellectual property rights of others, furnish
a draft of the proposed filing to ICN for review and comments at least thirty
(30) days in advance of filing. Any such draft shall be treated as Carme
Confidential Information and shall not constitute an offer to sell any product
to ICN. Carme and/or Senetek shall maintain and prosecute the Patents at their
own expense during the term of this Agreement. In the event Carme and Senetek
fail to maintain or prosecute any patent or patent application, they shall so
notify ICN and ICN may itself maintain and prosecute the same and deduct the
associated costs from any royalty due hereunder.

         5.2.6 Survival. The representations and warranties made in this
Agreement shall survive the termination of this Agreement for the longer of (a)
the statute of limitations applicable to claims for the breach of such
representation or warranty and (b) such other period as may be specified in this
Agreement.

6.       CONFIDENTIAL INFORMATION AND ANNOUNCEMENTS

     6.1 Carme Confidential Information. ICN shall not (a) use Carme
Confidential Information except to perform its obligations under this Agreement,
or (b) disclose Carme Confidential Information to any Person (except to its
employees and agents who reasonably require same for the purpose hereof and who
are bound to ICN by the same obligations as to

                                       12

<PAGE>

confidentiality) without the express written permission of Carme, unless such
disclosure is required by order of a court of competent jurisdiction.

     6.2 ICN Confidential Information. Carme shall not (a) use ICN Confidential
Information except to perform its obligations under this Agreement, or (b)
disclosed ICN Confidential Information to any Person (except to its employees
and agents who reasonably require same for the purpose hereof and who are bound
to Carme by the same obligations as to confidentiality) without the express
written permission of ICN, unless such disclosure is required by order of a
court of competent jurisdiction.

     6.3 No License. The furnishing of Confidential Information by one party to
the other shall not constitute any grant, option or license to the other under
any patent or other rights now or hereafter held by the furnishing party.

     6.4 Announcement. The parties will issue an agreed upon press release upon
execution of the agreement between ICN and Senetek Drug Delivery Technologies,
Inc. ("SDDT") described in section 9.2 below, or, if no such agreement is
reached and this Agreement is not voided within the time provided in section
9.2, then on November 2, 1998. Except for such release and except as may
otherwise be required by law, neither party will disclose the terms of this
Agreement to any other Person; provided, however, that each party may make such
disclosure of the terms of this Agreement to its employees and agents as is
necessary to permit such party to perform its obligations under this Agreement;
provided further that any such employee or agent agrees to maintain the
confidentiality of this Agreement. Except as may be required by law, neither
Carme nor Senetek will disclose the results of any clinical studies or other
technical data concerning the Products without ICN's approval, provided,
however, that Carme may make such disclosures (or permit disclosures) to show
that

                                       13

<PAGE>

products including Kinetin are more effective than those that do not include
Kinetin, provided further, that such permitted disclosures to the extent made by
Carme do not compare concentration levels of Kinetin.

     6.5 Survival. The provisions of this Article 5 shall survive termination of
this Agreement and continue for a period of ten (10) years.

7.       INDEMNIFICATION, INSURANCE AND LIMITS ON LIABILITY

     7.1 Indemnification of Carme. ICN shall defend, indemnify, and hold
harmless Carme, its offices, agents, employees and affiliates from any loss,
claim, action, damage, expense or liability (including defense costs and
attorneys' fees)(collectively, "Claims") arising out of or related to a breach
or alleged breach of any representation, warranty or covenant made by ICN
herein, or the handling, possession, marketing, sale or other use of the
Products, except insofar as such claims are related to or arise from Carme's
negligence or breach of this Agreement.

     7.2 Indemnification of ICN. Carme shall defend, indemnify, and hold
harmless ICN(less than symbol) its officers, agents, employees and affiliates
from any Claims arising out of or related to a breach or alleged breach of any
representation, warranty, or covenant made by Carme herein, or Carme's
manufacture or handling of the Products, except insofar as such claims are
related to or arise from ICN's negligence or breach of this Agreement.

     7.3 Insurance. ICN shall maintain at its expense commercial general
liability insurance in a principal amount of not less than the coverage
generally maintained by companies of similar size in the industry, but in no
event shall ICN be required to maintain coverage in excess of "*Filed Separately
with the Commission*" dollars per occurrence and "*Filed Separately with the
Commission*" in the aggregate. Such policy shall name Carme and Senetek as
additional insureds. Within thirty (30) calendar days after the date of this
Agreement, ICN

                                       14

<PAGE>

shall furnish to Carme certificate evidencing such insurance. Carme may elect
not to ship any product until such insurance is in place and the certificate of
coverage is provided, and may thereafter suspend shipment if it reasonably
believes such insurance is not in place until ICN provides Carme reasonable
assurance that such coverage is in place without any gap in coverage during the
Term and will be maintained as required by this Agreement.

     7.4 No Consequential Damages. Except for claims that include consequential
damagers paid to Persons that are not Affiliates of an indemnified party,
neither party shall be liable to the other for consequential damages, lost
profits, injury to reputation or similar claims. EXCEPT FOR CLAIMS BY THIRD
PARTIES ARISING FROM THE FAILURE OF THE PRODUCTS SUPPLIED BY CARME PURSUANT TO
THIS AGREEMENT TO CONFORM TO THE SPECIFICATIONS AT THE TIME OF SHIPMENT, AND
EXCEPT AS PROVIDED IN SECTION 8.3 BELOW UNDER NO CIRCUMSTANCES SHALL CARME OR
ITS AFFILIATES HAVE ANY LIABILITY ARISING FROM THIS AGREEMENT IN EXCESS OF THE
HIGHEST AGGREGATE AMOUNT PAID AS BASE PRICE AND ROYALTIES OVER THE COURSE OF ANY
TWO CONTRACT YEAR PERIOD.

8.       RECALLS

     8.1 Responsibility. In the event any Product(s) must be recalled from the
channel of distribution by reason of failure to meet any requirements or law or
otherwise, ICN shall have the sole responsibility to effect the recall. Carme
shall use its reasonable best efforts to cooperate with ICN in implementing any
such recalls to the extent such cooperation is necessary to effect the recall.

     8.2 Reimbursement of Carme. In the event the recall results from or is
caused by an act or omission by ICN, ICN shall reimburse Carme for any costs
and/or expenses reasonably expended by Carme as a consequence of the recall.
Without limiting the general nature of the

                                       15

<PAGE>

foregoing, ICN shall bear the cost of (a) any Kinetin involved in such recall,
(b) any other raw materials used to produce recalled products, and (c) the Base
Fee for any Products that are recalled and for any other finished Products that
cannot be shipped due to the condition requiring the recall.

     8.3 Reimbursement of ICN. In the event the recall results from or is caused
by an act or omission of Carme, Carme shall reimburse ICN for any costs and/or
expenses reasonably expended by ICN as a consequence of the recall. Without
limiting the general nature of the foregoing, Carme will provide replacement
Products for recalled Products and for any Products that cannot be shipped due
to the condition requiring the recall.

9.       TERM AND TERMINATION

     9.1 Term. The term of this Agreement shall be the Term unless early
terminated pursuant top Section 9.2.

     9.2 Termination. Each party shall have the right to terminate this
Agreement at any time upon written notice to the other in the event (i) the
other party fails to perform any material obligation and such failure continues
for a period of thirty (30) days after notice thereof with respect to a payment
failure or, with respect to any other failure, such failure continues for a
period of sixty (60) days after notice thereof, (ii) the other party is declared
insolvent or bankruptcy by a court of competent jurisdiction, or a voluntary
petition of bankruptcy is filed in any court of competent jurisdiction by the
other party, or the other party makes or executes any assignment for the
benefits of creditors, or (iii), ICN fails to meet any Minimum Purchase
Requirement or satisfy the Promotion Commitment. In addition, ICN may terminate
this Agreement without cause at any time after the end of the first Contract
Year upon six (6) months' written notice to Carme. This agreement shall be
voidable ab initio on written notice by either party to the other in the event
ICN and Senetek Drug Delivery Technologies, Inc.

                                       16

<PAGE>

("SDDT") do not conclude a final distribution agreement covering SDDT's
Reliaject Autoinjector containing epinephrine by October 23, 1998, provided that
such notice must be given, if at all, no later than October 30, 1998.

10.      MISCELLANEOUS

     10.1 Method of Payments. All payments due under this Agreement shall be
paid in U.S. Dollars in cash by a check drawn on a United States bank or by wire
transfer of immediately available funds.

     10.2 No Joint Venture. It is not the intent of the parties hereto to form
any partnership or joint venture. Each Party shall, in relation to its
obligations hereunder, act as an independent contractor, and nothing in this
Agreement shall be construed to give either party the power or authority to act
for, bind or commit the other.

     10.3 Governing Law. This Agreement shall be governed by and interpreted in
accordance with the laws of the State of California (regardless of that or any
other jurisdiction's choice of law principles).

     10.4 No Assignment. Neither party to this Agreement may assign its rights
or obligations under this Agreement without the prior written consent of the
other party to this Agreement; provided, however, that either party may assign
its rights to a person that acquires substantially all of the assets of such
party; provided further, that no such assignment shall relive the assigning
party of its obligations under this Agreement.

     10.5 Force Majeure. No party hereto shall be liable to any other in damages
for, nor shall this Agreement by terminable by reason of, any delay or default
in such party's performance hereunder if such delay or default is caused by
conditions beyond such party's control including, but not limited to, acts of
God, regulation or law or other action of any government or any agency thereof,
war, insurrection, civil commotion, destruction of production

                                       17

<PAGE>

facilities or materials by earthquake, fire, flood or storm, labor disturbances,
epidemic, or failure of suppliers, public utilities or common carriers. Each
party hereto agrees to promptly notify the other party of any event of force
majeure under this Section 11.5 and to employ all reasonable efforts towards
prompt resumption of its performance hereunder when possible if such performance
is delayed or interrupted by reason of such event.

     10.6 Notices. Unless otherwise provided herein, any notice required or
permitted to be given hereunder (a "Notice") shall be mailed by certified mail
or generally recognized express courier service with signature required for
delivery, postage prepaid, or delivered by hand to the party to whom such Notice
is required or permitted to be given hereunder. If mailed, any such Notice shall
be deemed to have been given as of the date of receipt, as evidenced by the date
appearing on the delivery notice. If delivered by hand, any such Notice shall be
deemed to have been given when received by the party or agent of such party to
whom such Notice is given, as evidenced by written and dated receipt of the
receiving party.

                  All Notices to ICN shall be addressed as follows:
                  ICN Pharmaceuticals, Inc.
                  ICN Plaza
                  3300 Hyland Avenue
                  Costa Mesa, CA  92626
                  Attn.:  General Counsel

                  All Notices to Carme shall be addressed as follows:
                  Carme Cosmeceutical Sciences, Inc.
                  620 Airpark Road
                  Napa, CA  94558

Either party may change the address to which any Notice is to be addressed by
notification to the other party as provided herein.

     10.7 Captions. The captions in this Agreement are solely for convenience of
reference and shall not be used for purposes of interpreting or construing the
provisions hereof.

                                       18

<PAGE>

     10.8 Severability. Should any part or provision of this Agreement be held
unenforceable or in conflict with the applicable laws or regulations of any
jurisdiction, the invalid or unenforceable part or provision shall be replaced
with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner,
and the remainder of this Agreement shall remain binding upon the parties
hereto.

     10.9 Waiver. No failure on the part of any party hereto to exercise, and no
delay in exercising, any right, privilege or power hereunder shall operate as a
waiver or relinquishment thereof; nor shall any single or partial exercise by
any party hereto of any right, privilege or power hereunder preclude any other
or further exercise thereof, or the exercise of any other right, privilege or
power.

     10.10 Entire Agreement. This Agreement together with its Schedules and
Exhibits constitute the entire agreement and understanding between the parties
hereto with respect to the subject matter of this Agreement and shall supersede
any prior agreements, negotiations, understandings, representations, statements
and writings thereto. This Agreement may not be amended or modified except in a
writing signed by a duly authorized officer of the party against whom
enforcement of such amendment is sought.

     10.11 Counterparts. This Agreement may be executed in one or more
counterparts by exchange of facsimile copies of signature pages, each of which
will be deemed an original and all of which together will constitute one and the
same instrument.

     10.12 Document Preparation. The Parties acknowledge that this Agreement is
a product of extensive negotiations and that no inference should be drawn
regarding the preparation of this document.

                                       19

<PAGE>

                  To evidence this Agreement, the parties have caused their duly
authorized representatives to execute this Agreement as of the date first
written above.

                                       20

<PAGE>

                            ICN PHARMACEUTICALS, INC.

                            By:      /s/ Bill A. MacDonald
                                 ---------------------------------------
                            Name:    Bill A. MacDonald
                                  -----------------------------
                            Title:   Executive Vice President
                                    ---------------------------

                            CARME COSMECEUTICAL SCIENCES, INC.

                            By:      /s/ Frank J. Massino
                                 ---------------------------------------
                            Name:  Frank J. Massino
                                   ----------------------------
                            Title:   President
                                    ------------------------------------

                            approved by:

                            SENETEK, PLC

                                       By: /s/ Anthony J. Cataldo
                                           -----------------------
                            Name: Anthony J. Cataldo

                            Title: Chairman and CEO

                                       21

<PAGE>
                                    EXHIBIT A

                                     PATENTS

  (List to include all patents and patent applications for Kinetin worldwide.)

                                       22

<PAGE>

                                    EXHIBIT B

                    "*Filed Separately with the Commission*"

                                       23

<PAGE>

                                    EXHIBIT C

                    "*Filed Separately with the Commission*"

                                       24

<PAGE>

                                    EXHIBIT D

                    "*Filed Separately with the Commission*"

                                       25<PAGE>
                                                                   Exhibit 10.49

                          LICENSE AND SUPPLY AGREEMENT

***Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended, and the Commission's rules and
regulations promulgated under the Freedom of Information Act, pursuant to a
request of confidential treatment.

         This License and Supply Agreement (this "Agreement") is made as of May
26, 2000 (the "Effective Date") by and between SENETEK PLC, a British public
limited company ("Senetek"), with an office at 620 Airpark Road, Napa,
California 94588, and BUTH-NA-BODHAIGE, INC., a Delaware corporation, doing
business as The Body Shop ("The Body Shop"), with the Marketing and Product
Development office at 1440 Chapin Avenue, Suite 200, Burlingame, California
94010 and the Operations and Warehouse facility at 5036 One World Way, P.O. Box
1409 Wake Forest, NC 27587.

                                    RECITALS:
                                    --------
         A. The Body Shop wishes to purchase from Senetek, and to acquire a
license to market, distribute and sell the products using Kinetin described in
Exhibit A (the "Products") pursuant to the terms and conditions set forth in
this Agreement.

         B. Senetek is willing to sell to The Body Shop, and to grant a license
to The Body Shop to market, distribute and sell the Products pursuant to the
terms and conditions set forth in this Agreement.

         Accordingly, in consideration of the premises and the mutual covenants
and undertakings set forth in this Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which are acknowledged, the
parties agree as follows:

                                    ARTICLE I
                                    ---------
                                   DEFINITIONS
                                   -----------
         1.1 As used in this Agreement, the following capitalized terms shall
have the following respective meanings:

         "Affiliate" means (a) any company owned or controlled to the extent of
at least fifty percent (50%) of its issued and voting capital securities by a
party to this Agreement and any other company so owned or controlled (directly
or indirectly) by any such company or the owner of any such company, or (b) any
partnership, joint venture or other entity directly or indirectly controlled by,
controlling, or under common control of, to the extent of fifty percent (50%) or
more of voting power (or otherwise having power to control its general
activities) by a party to this Agreement, but in each case only for so long as
such ownership or control shall continue.

         "Body Shop Catalog" means catalogs published by The Body Shop under The
Body Shop Brand offering only products generally available at retail outlets
operated by the Body Shop under the name The Body Shop.

         "Body Shop Website" means a web site operated by The Body Shop under
The Body Shop Brand with the top level uniform resource locator of
[www.TheBodyShop.com] offering

<PAGE>

only products generally available at retail outlets operated by the Body Shop
under the name The Body Shop.

         "Contract Year" means a period from January 1 of a calendar year
through December 31 of the same calendar year; provided that the first Contract
Year shall commence on January 1, 2001, the Effective Date and continue until
December 31, 2001.

         "Dollar", "Dollars" or "$" means the legal currency of the United
States of America.

         1.1 "Improvement" means any information, discovery, creation,
derivative work, invention, or trade secret, whether or not patented or
patentable or copyrighted or copyrightable, that relates to or is based upon the
Intellectual Property and is developed or otherwise acquired by either party,
their Affiliates or any of their respective employees, officers or agents.

         "Indemnifiable Damages" means with respect to any claim for
indemnification, the aggregate amount of all losses, claims, damages,
liabilities, costs, expenses or deficiencies to which either party or any other
person or entity is entitled to indemnification hereunder.

          "Intellectual Property" means (i) patents and patent applications,
(ii) trademarks, trade names, service marks and registrations and applications
for registrations thereof (including, but not limited to, "kinetin" and analogs
thereof), (iii) copyrights and copyright registrations, (iv) trade secrets and
secret processes, and (v) other Know How, in each case relating to the Products
(or any Product) and in the United States of America and each Territory.

         1.2 "Know-How" means such know-how, special knowledge, data, studies,
technical or other information, whether or not patented or patentable, owned or
controlled by Senetek or its Affiliates at any time prior to or during the Term
specifically related to the development, manufacture or use of the Product.

         "Mass Market" means the cosmetic market channel generally known in the
industry as the mass market channel to include Drug Store, Discount and Food
Stores.

         "Prestige Market" means the cosmetic market channel created by high-end
department store cosmetic counters and by perfumeries, and generally known in
the industry as the prestige market channel.

         "The Body Shop Confidential Information" means marketing, sales,
financial, scientific, and other non-public and/or proprietary information
concerning the products, projects, business and operations of The Body Shop
including the manufacture, use, or sale of the Products disclosed by The Body
Shop to Senetek.

          "Senetek Confidential Information" means marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Senetek including the
manufacture, use, or sale of the Products disclosed by Senetek to The Body Shop.

         "Senetek Gross Margin" means, with respect to a Unit, the gross margin
calculated in accordance with past practice by Senetek's independent auditors.

                                       2

<PAGE>

         "Term" means the period commencing on the Effective Date and concluding
(unless earlier terminated pursuant to the terms herein) on the tenth
anniversary of the Effective Date.

         "Territory" means North America.

         "The Body Shop Brand" means the term "The Body Shop."

         "The Body Shop Competitors" means Bath & Body Works, Garden Botanika,
Origins, Aveda and The Limited Group of companies.

         "The Body Shop Gross Margin" means, with respect to a Unit, a ratio the
numerator of which equals the initial selling price for such Unit less the
amount paid to Senetek for such Unit and the denominator of which is the initial
selling price for such Unit.

         "Unit" means an individual packaged unit of Product, but shall not
include any individual packaged Unit with a sale price of less than "*Filed
Separately with the Commission*".

                                   ARTICLE II
                                   ----------
                           PURCHASE, SALE AND LICENSE
                           --------------------------

         2.1 During the Term, Senetek agrees to supply and deliver to The Body
Shop, and The Body Shop agrees to purchase from Senetek, Products in such
quantities as The Body Shop requests. All orders for Products shall be made
pursuant to written purchase orders delivered to Senetek in accordance with
Article IV.

         2.2 Senetek hereby grants to The Body Shop a license to market and sell
the Products to individual consumers under The Body Shop Brand (i) in stores
operated with the name "The Body Shop" by The Body Shop in the Territories, (ii)
through the Body Shop Catalog for delivery in the Territory, (iii) on the Body
Shop Website for delivery in the Territory. All other rights are reserved to
Senetek and (iv) non-physician operated spa outlets excluding salons.

         2.3 Senetek agrees that, for so long during the Term as The Body Shop
orders at least "*Filed Separately with the Commission*". Units during each
Contract Year, it will not sell the Products to Body Shop Competitors (the
"Exclusivity Commitment"). Units for which The Body Shop does not make payment
within the time permitted by this Agreement will not count towards the minimum
order requirement. If The Body Shop fails to meet the minimum order requirement
in any Contract Year, (i) the Exclusivity Commitment shall terminate for the
balance of the Term and (ii) Senetek may terminate this Agreement at any time
upon not less than 180 days written notice to The Body Shop. It is expressively
understood that there is no exclusivity granted for the spa market.

         2.4 During the Term, for so long as the Exclusivity Commitment is in
effect, The Body Shop shall have a right of first offer to obtain a license to
market and sell all advanced and improved Kinetin cosmeceutical products and
formulations of a concentration of "*Filed Separately with the Commission*" or
less developed in the future by Senetek, including, without limitation,
cosmeceutical products to be developed by Senetek in collaboration with the

                                       3

<PAGE>

University of Aarhus. The Body Shop shall have thirty (30) days from written
notice given by Senetek that any such new product is or may become available for
distribution and sale to deliver an offer to Senetek setting forth an offer to
purchase, market, and sell such new product. During the thirty (30) day period
after such offer, Senetek and The Body Shop shall negotiate in good faith to
reach a formal agreement. If Senetek elects, in its sole discretion, not to
accept The Body Shop's offer, or if The Body Shop does not make an offer within
the aforementioned thirty (30) day period, Senetek shall be free to (a) grant
such rights for such new product to other parties, or (b) exercise such rights
itself. If Senetek elects to accept The Body Shop's offer, the Exclusivity
Commitment shall extend to the new products and formulations for which Senetek
has made such offer, it being expressly understood that nothing shall restrict
Senetek from increasing minimum purchase requirements as a condition of
accepting any offer.

         2.5 It is expressly understood that this Agreement grants no rights to
The Body Shop for the marketing or sale of the Products or under any patents
related thereto except those express rights set forth in Sections 2.1 through
2.4. Without limiting the foregoing, it is understood and agreed that The Body
Shop has no right pursuant to this Agreement to, and shall not, (i) sell the
Products outside the Territory or within the Territory other than at The Body
Shop stores operated by The Body Shop, (ii) sell Products under any brand or
with labeling other than the The Body Shop Brand, (iii) manufacture or have made
other than by Senetek or its designee any Products or (iv) have any right with
respect to Improvements except as set forth in Section 2.4. Upon any termination
of this Agreement, The Body Shop shall have no right of any kind with respect to
the Products, Patents, Improvements or Marks other than the right to complete
the sale within six months of such termination of Products then lawfully in its
possession.

         2.6 The parties will negotiate in good faith for a period of 30 days
beginning on the Effective Date to extend the Territory to include those
countries outside North America where The Body Shop now operates retail stores
under the name The Body Shop and to increase the minimum purchase commitment to
reflect such expansion of the Territory. If the parties are unable to reach an
agreement with respect to such additional territory within such 30 day period,
Senetek shall have no further obligation to The Body Shop with respect to such
additional territory.

                                   ARTICLE III
                                   -----------
                            TERMS OF LICENSE AND SALE
                            -------------------------

         3.1      "*Filed Separately with the Commission*".

         3.2 The Body Shop will pay 50% of the amount due with respect to its
first order upon placement of the order and the balance due (including shipping
costs) with respect to such order within 30 days after delivery of the Products
fulfilling the first order. The Body Shop will pay the full amount due
(including shipping costs) with respect to any other order within 30 days of
delivery of the Products fulfilling such order. Late payments shall be subject
to a monthly processing fee of "*Filed Separately with the Commission*" of the
amount overdue or, if such amount is not permitted by law, the maximum amount
permitted by law.

                                       4

<PAGE>

3.3 The Body Shop shall pay shipping costs from Senetek's place of manufacture.
Senetek will use the shipper specified by The Body Shop and will address the
Products for delivery to the location specified by The Body Shop in the order;
provided, however, that the Body Shop may not specify a delivery point outside
the Territory. If The Body Shop does not specify a shipper, Senetek may ship
freight collect using a shipper of its choice to the location last specified by
The Body Shop or if no location has been previously specified, to The Body
Shop's Wake Forest warehouse located at 5036 One World Way, P.O. Box 1409 Wake
Forest, NC 27587.

         In all cases, risk of loss and damage shall shift to The Body Shop upon
delivery of the Product to the shipper.

         3.4 Each party shall keep books and records sufficient to permit each
party to verify the other's Gross Margin. Such books and records shall be
preserved for a period not less than two (2) years after they are created during
and after the Term of this Agreement.

         3.5 Each party shall take commercially reasonable steps necessary to
verify the accuracy of the other party's accounting for its Gross Margin based
on The Body Shop's Retail Selling price for each product at that time of sale.
Each party shall conduct no more than one (1) review during any Contract Year.

                                   ARTICLE IV
                                   ----------
                          FORECASTS, SHIPMENTS, ORDERS
                          ----------------------------

         4.1 Within the first ten business days of the third month of the Term
and every third month thereafter, The Body Shop shall provide Senetek with an
updated forecast (with volumes and delivery dates specified for each Product) of
The Body Shop's Product purchases during the next following twelve (12) month
period (but not extending beyond the Term). The Body Shop shall provide its
initial forecast for the first Contract Year contemporaneously with its
execution of this Agreement. Products may be ordered by The Body Shop in such
quantities as The Body Shop may from time notify Senetek pursuant to a purchase
order in the form attached as Exhibit B (a "Purchase Order"). Senetek shall use
commercially reasonable efforts to deliver Products within 90 days after the
date of the Purchase Order for such Products (or on such later date as the
Purchase Order may specify).

         4.2 Senetek shall not be obligated to deliver Products in lot sizes
smaller than as specified in Exhibit A (To be determined based on product
packaging and shippers).

         4.3 The Products shall be packaged and labeled as set forth in Exhibit
C (packaging, copy and layouts are to be determined, and will be forwarded when
approved by The Body Shop). All packaging shall state that Kinetin is patented,
that it is proprietary technology of Senetek, and that the Kinetin logo mark is
a registered trademark of Senetek. The Body Shop grants to Senetek a license to
utilize the trademarks, service marks and other intellectual property necessary
to package and label the Products as specified in Exhibit C (the "Packaging
License"). The Packaging License shall expire upon the termination of this
Agreement.

                                       5

<PAGE>

         4.4 Senetek will engage "*Filed Separately with the Commission*" for
finish manufacturing of the Products sold to The Body Shop. Senetek may engage
other parties for finish manufacturing of such Products only with the consent of
The Body shop, which consent will not be unreasonably withheld or delayed.

                                    ARTICLE V
                                    ---------
                         MARKETING; REGULATORY APPROVALS
                         -------------------------------

         5.1 The Body Shop shall undertake commercially reasonable steps to
market and promote the Products in its stores and in advertising of The Body
Shop's products.

         5.2 Except as provided below in this Section 5.2, The Body Shop shall
be solely responsible for and shall take commercially reasonable actions to
register the Products for sale in, and obtain all other governmental approvals
necessary to sell the Products from the government of, each Territory. Senetek
shall provide commercially reasonable assistance to The Body Shop in connection
with, and shall promptly provide The Body Shop with all necessary information
within its possession for, the full and legal registration of Products in each
Territory.

         5.3 Promptly after the execution of this Agreement, the parties will
issue a joint press release concerning the Products, which press release will be
drafted by Senetek subject to the review and approval of The Body Shop. Senetek
shall submit to The Body Shop for review and approval, prior to release, all
communications containing any information relating to The Body Shop. The Body
Shop shall submit for review and approval, prior to release, all public
communications containing any information relating to Senetek, its Affiliates or
the Products. Notwithstanding the foregoing, each party agrees that the other
may make such public statements as are required by applicable securities laws or
the rules of any exchange on which securities of such party or its Affiliates
are listed. The Body Shop will submit all promotion materials including
packaging for the Products to Senetek for approval prior to use, which approval
will not be unreasonably delayed or denied. All such promotional materials will
incorporate information concerning the antioxidant properties of Kinetin. No
such promotional materials, including packaging, will make unsubstantiated
claims concerning the effectiveness of Kinetin or claims based upon
concentration levels.

                                   ARTICLE VI
                                   ----------
                    REPRESENTATIONS, WARRANTIES AND COVENANTS
                    -----------------------------------------

         6.1 Each of the parties hereto represents and warrants to the other
that: (i) it is duly organized, validly existing and in good standing in
accordance with the laws of its jurisdiction of organization; (ii) it has all
requisite legal and corporate power and authority to enter into and perform its
obligations under this Agreement; (iii) it has duly authorized the entry into
and performance of its obligations under this Agreement by all requisite
corporate actions; (iv) when executed by the corporate officers whose names
appear on the signature page hereof, this Agreement shall be a legal, valid and
binding obligation of such party enforceable in accordance with its terms,
subject to bankruptcy, insolvency and similar laws affecting creditors' rights
generally and general principles of equity; (iv) its execution and delivery and
performance of its obligations under this Agreement do not breach, violate,
conflict with or contravene in any

                                       6

<PAGE>

material respect (A) its organizational documents, (B) any laws, rules,
regulations, orders, judgments or decrees applicable to or binding upon such
party or its property, or (C) any other agreement, instrument, mortgage,
indenture, contract, license or other document to which it is a party or by
which it is bound; (v) it has obtained all governmental and third party consents
and made all filings and notices required in connection with its execution,
delivery and performance of this Agreement, and all such consents, filings and
notices remain in full force and effect; and (vi) it will comply in all material
respects with all applicable laws, rules and regulations in the conduct of its
responsibilities and activities under this Agreement.

         6.2 Senetek represents, warrants and covenants to The Body Shop that:
(a) all Products will conform in all material respects to the specifications set
forth in Exhibit D - The Body Shop Supplier Guideline Document; (b) Senetek and
to the knowledge of Senetek the manufacturer(s) of all Products have and will
comply in all material respects with good manufacturing practices and all laws,
regulations, rules and orders covering the production, sale and delivery of
Products the failure to comply with which would cause a material liability to
accrue to The Body Shop; and (c) Senetek or its Affiliates has, and throughout
the Term at all times shall maintain at Senetek's sole expense, such right,
title and interest in all Intellectual Property (other than the Packaging
License and other Intellectual Property owned by The Body Shop) necessary to
grant the rights granted to The Body Shop in this Agreement in the Territory;
there are no interference, opposition or cancellation proceedings pending or, to
the knowledge of Senetek, threatened against Senetek or the Intellectual
Property relating to the Products; no claim, suit or action is pending to which
Senetek is a party or, to Senetek's knowledge, threatened alleging that any
Product is infringing or would infringe upon the Intellectual Property rights of
others.

         6.3 The Body Shop represents, warrants and covenants to Senetek that
the Packaging License includes all the Intellectual Property rights necessary
for Senetek to produce the packaging and labeling required by this Agreement.

         6.4 The Body Shop represents, warrants and covenants that it does not
operate stores in and will not sell the Product in the Prestige Market
(Department Stores) or the Mass Market; The Body Shop reserves the right to
market in Spa Markets.

         6.5 Senetek will undertake commercially reasonable steps to defend and
enforce the patents included in Intellectual Property.

         6.6 The Body Shop will use commercially reasonable efforts to commence
sales of the Products in its stores in the Territory on or before January 1,
2001 but in any event by March 31, 2001, provided that Senetek timely delivers
Products ordered in accordance with the terms of this Agreement.

         6.6 Except as expressly set forth in this Agreement, neither party
makes any representations, warranties or covenants to the other. ALL IMPLIED
WARRANTIES INCLUDING ANY WARRANTY OF FITNESS FOR A PARTCULAR PURPOSE OR OF
MERCHANTABILITY ARE HEREBY EXPRESSLY EXCLUDED.

                                       7

<PAGE>

                                   ARTICLE VII
                                   -----------
                           INDEMNIFICATION; INSURANCE
                           --------------------------

         7.1 The Body Shop shall defend, indemnify, and hold harmless Senetek,
its officers, agents, employees and Affiliates from any Indemnifiable Damages
arising out of or related to a breach of any representation, warranty or
covenant made by The Body Shop herein, or the handling, possession, marketing,
sale or other use of the Products (including the use of the Packaging License),
except insofar as such claims are related to or arise from Senetek's negligence
or breach of this Agreement.

         7.2 Senetek shall defend, indemnify, and hold harmless The Body Shop,
its officers, agents, employees and affiliates from any Indemnifiable Damages
arising out of or related to a breach or alleged breach of any representation,
warranty, or covenant made by Senetek herein, or the manufacture or handling of
the Products by Senetek, except insofar as such claims are related to or arise
from The Body Shop's negligence or breach of this Agreement.

         7.3 In the event of any such claim or action by any third party, the
party seeking indemnification hereunder (the "Indemnified Party") agrees: (i) to
give the party required to indemnify the Indemnified Party (the "Indemnifying
Party"), reasonably prompt notice of the claim or action; and (ii) to provide
the Indemnifying Party with information, assistance and authority necessary, at
the Indemnifying Party's expense, to enable the Indemnifying Party to defend
such claim or action. After receipt of any such notice, the Indemnifying Party
shall have the right to (x) take control of the defense and investigation of
such lawsuit or action, (y) employ and engage attorneys of its own choice to
handle and defend the same, at the Indemnifying Party's sole cost and expense,
and (z) compromise or settle such claim, which compromise or settlement shall be
made only with the written consent of the Indemnified Party (such consent not to
be unreasonably withheld, delayed or denied); provided, however, no such consent
will be required if such settlement provides solely for payment of monetary
damages for which the Indemnified Party will be Indemnified in full. The
Indemnified Party may participate in the investigation, trial and defense of any
such third party action and any appeal arising therefrom at its sole cost and
expense.

         7.4 In the event any Intellectual Property infringement claim for which
Senetek is obligated to indemnify The Body Shop pursuant to Section 7.1 of this
Agreement is made, Senetek may elect in its sole and absolute discretion to do
any or none of the following:

         (a) procure such license as is necessary for The Body Shop's past
         rights and future rights to continue to exercise all rights granted
         with respect to the Product(s) under this Agreement;

         (b) replace or modify the allegedly infringing item(s) to avoid the
         infringement, without materially impairing performance or compliance
         with the Product's specifications to The Body Shop's reasonable
         satisfaction, or

                                       8

<PAGE>

         (c) if neither the procuring of such a license nor the replacement or
         modification as above-described are economically practicable, accept
         return of all the Product(s) purchased.

         7.5 Each party's obligations under this Article VII shall survive the
expiration of the Term indefinitely.

         7.6 Senetek shall maintain a product liability policy relating to any
use of the Products at any time during the Term of this Agreement with coverage
of not less than one (1) million dollars per occurrence, which policy shall name
The Body Shop as an additional insured. Within thirty (30) calendar days after
the date of this Agreement, Senetek shall furnish to The Body Shop certificates
evidencing such insurance. The Body Shop shall maintain at its expense
commercial general liability insurance in a principal amount of not less than
the coverage generally maintained by companies of similar size in the industry.
Within thirty (30) calendar days after the date of this Agreement, The Body Shop
shall furnish to Senetek certificates evidencing such insurance. Senetek may
elect not to ship any Product until such insurance is in place and certificates
of coverage are provided, and may thereafter suspend shipment if it reasonably
believes such insurance is not in place until The Body Shop provides Senetek
reasonable assurance that such coverage is in place.

                                  ARTICLE VIII
                                  ------------
                            CONFIDENTIAL INFORMATION
                            ------------------------

         8.1 The Body Shop shall not (a) use Senetek Confidential Information
except to perform its obligations under this Agreement, or (b) disclose Senetek
Confidential Information to any person or entity (except to its employees and
agents who reasonably require same for the purpose hereof and who are bound to
The Body Shop by the same obligations as to confidentiality) without the express
written permission of Senetek, unless such disclosure is required by order of a
court of competent jurisdiction.

         8.2 Senetek shall not (a) use The Body Shop Confidential Information
except to perform its obligations under this Agreement, or (b) disclose The Body
Shop Confidential Information to any person or entity (except to its employees
and agents who reasonably require same for the purpose hereof and who are bound
to Senetek by the same obligations as to confidentiality) without the express
written permission of The Body Shop, unless such disclosure is required by order
of a court of competent jurisdiction.

         8.3 The furnishing of confidential information by one party to the
other shall not constitute any grant, option or license to the other under any
patent or other rights now or hereafter held by the furnishing party.

         8.4 The provisions of this Article VIII shall survive termination of
this Agreement and continue for a period of ten (10) years.

                                       9

<PAGE>

                                   Article IX
                                   ----------
                                    RECALLS
                                    -------

         9.1 In the event any Product(s) must be recalled from the channel of
distribution by reason of failure to meet any requirements of law or otherwise,
The Body Shop shall have the sole responsibility to effect the recall. Senetek
shall use its reasonable best efforts to cooperate with The Body Shop in
implementing any such recalls to the extent such cooperation is necessary to
effect the recall.

         9.2 In the event the recall results from or is caused by an act or
omission by The Body Shop, The Body Shop shall reimburse Senetek for any costs
and/or expenses reasonably expended by Senetek as a consequence of the recall.
Without limiting the general nature of the foregoing, The Body Shop shall bear
the cost of (a) any Product involved in such recall, (b) any other raw materials
used to produce recalled Products, and (c) the purchase price payable pursuant
to Section 3.2 for any Products that are recalled and for any other finished
Products that cannot be shipped due to the condition requiring the recall.

         9.3 In the event the recall results from or is caused by an act or
omission of Senetek, Senetek shall reimburse The Body Shop for any costs and/or
expenses reasonably expended by The Body Shop as a consequence of the recall.
Without limiting the general nature of the foregoing, Senetek will provide
replacement Products for recalled Products and for any Products that cannot be
shipped due to the condition requiring the recall.

                                    ARTICLE X
                                    ---------
                                   TERMINATION
                                   -----------

         10.1     Each party shall have the right, but not the obligation to
                  terminate this Agreement at any time upon written notice to
                  the other in the event (i) the other party fails to perform
                  any material obligation and such failure continues for a
                  period of thirty (30) days after notice thereof with respect
                  to a payment failure or, with respect to any other failure,
                  such failure continues for a period of sixty (60) days after
                  notice thereof, or (ii) the other party is declared insolvent
                  or bankrupt by a court of competent jurisdiction, or a
                  voluntary petition of bankruptcy is filed in any court of
                  competent jurisdiction by the other party, or the other party
                  makes or executes any assignment for the benefit of creditors.
                  In the event of any termination other than solely as a result
                  of the material default of Senetek in the performance of its
                  obligations under this Agreement, The Body Shop agrees to
                  purchase from Senetek at Senetek's fully allocated cost all
                  materials including but not limited to packaging, chemicals
                  and raw materials, that have been ordered with respect to a
                  Purchase Order or to meet purchases predicted in the
                  projections required under this Agreement for the period
                  beginning on the termination date and ending three months
                  after the termination date.

         10.2     The Body Shop shall have the right, but not the obligation to
                  terminate this Agreement at anytime upon written notice to
                  Senetek in the event:

                                       10

<PAGE>

                  a) Safety and Efficacy Data Validation generated by Senetek
                  during the past 10 years based on Animal Testing (data used
                  must not be based on Animal Testing).

                  b) If the UC Irvine data does not support the claim that
                  Kinetin containing formulations ameliorate roughness, mottled
                  hyperpigmentation and reduction of TEWL.

                  c) If the in-vitro cellculture data generated by the
                  University of Aarhus does support the delay or prevention of
                  cellular changes invitro in natural aging as based on the
                  Rattan publication found in Biochem. and Biophys. Res Common
                  1994; 201: 665-72.

                                   ARTICLE XI
                                   ----------
                                  MISCELLANEOUS
                                  -------------
         11.1 The validity, interpretation and performance of this Agreement
shall be governed and construed in accordance with the internal laws (without
application of conflict of laws principles thereof) of the State of California.

         11.2 Except as otherwise provided herein, neither party may assign this
Agreement without the prior written consent of the other party hereto. This
Agreement shall be binding upon, and inure to the benefit of, The Body Shop and
Senetek and their respective successors and permitted assigns.

         11.3 This Agreement constitutes the full understanding of the parties
and is a complete and exclusive statement of the terms of their agreement. All
prior agreements, negotiations, dealings and understandings, whether written or
oral, regarding the subject matter hereof, are hereby superseded and merged into
this Agreement.

         11.4 This Agreement shall not be modified, rescinded or waived except
in writing signed by the party to be bound thereby.

         11.5 Any notice, request, approval or other document required or
permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given when delivered in person or by courier
service of established reputation to the President of the subject party at the
address for such subject party specified in the Preamble hereto or to such other
address as may be specified from time to time in a written notice to the other
party.

         11.6 Article headings are provided for convenience of the parties only
and shall not be construed as a part of this Agreement or a limitation on the
scope of the particular sections and articles to which they refer.

         11.7 If any term or provision of this Agreement or any application
thereof shall be invalid or unenforceable, the remainder of this Agreement or
any other application of such term or provision shall not be affected hereby.

                                       11

<PAGE>

         11.8 This Agreement may be executed in two or more counterparts, each
of which shall constitute an original and all of which together shall constitute
a single instrument.

         11.9 EXCEPT FOR CLAIMS THAT INCLUDE CONSEQUENTIAL DAMAGES PAID TO
PERSONS THAT ARE NOT AFFILIATES OF AN INDEMNIFIED PARTY AND FOR CLAIMS ARISING
FROM THE SALE OF PRODUCT BY THE BODY SHOP IN VIOLATION OF THE LICENSE GRANTED BY
THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR CONSEQUENTIAL,
PUNITIVE, EXEMPLARY, INCIDENTAL OR SPECIAL DAMAGES, LOST PROFITS, INJURY TO
REPUTATION OR SIMILAR CLAIMS. UNDER NO CIRCUMSTANCES SHALL SENETEK OR ITS
AFFILIATES HAVE ANY LIABILITY ARISING FROM OR UNDER ANY PROVISION OF THIS
AGREEMENT IN EXCESS OF THE HIGHEST AGGREGATE AMOUNT PAID FOR PRODUCTS OVER THE
COURSE OF ANY SINGLE CONTRACT YEAR.

         11.10 It is not the intent of the parties hereto to form any
partnership or joint venture. Each party shall, in relation to its obligations
hereunder, act as an independent contractor, and nothing in this Agreement shall
be construed to give either party the power or authority to act for, bind or
commit the other.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                   SENETEK PLC

                                   By:      /s/ Frank J. Massino
                                            -----------------------------------
                                   Name:    Frank J. Massino
                                            -----------------------------------
                                   Title:   Chief Executive Officer
                                            -----------------------------------

                                   BUTH-NA-BODHAIGE, INC. D/B/A THE BODY SHOP

                                   By:      /s/ Carla Gervasio/Peter Saunders
                                            -----------------------------------
                                   Name:    Carla Gervasio/Peter Saunders
                                            -----------------------------------
                                   Title:   Vice President/Chief Executive
                                            -----------------------------------

                                       12

<PAGE>

                                    EXHIBIT A

                    "*Filed Separately with the Commission*"

                                       13

<PAGE>

                                    EXHIBIT B

                             FORM OF PURCHASE ORDER

                                  Copy Attached

                                       14

<PAGE>

                                    EXHIBIT C

                                    PACKAGING

                          (Under Development-To Follow)

                                       15

<PAGE>

                                    Exhibit D

          The Body Shop Supplier Guidelines Manual - Attached Hard Copy

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]